VectivBio Holding AG (VECT)
| Market Cap | 175.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.94M |
| Shares Out | 35.86M |
| EPS (ttm) | -5.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,648 |
| Open | 4.81 |
| Previous Close | 5.00 |
| Day's Range | 4.81 - 5.04 |
| 52-Week Range | 2.74 - 37.70 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.50 (+420.4%) |
| Earnings Date | n/a |
About VECT
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VECT stock is "Strong Buy." The 12-month stock price forecast is 25.50, which is an increase of 420.41% from the latest price.
News
VectivBio Announces Third Quarter 2021 Business Update
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-
VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...
VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease
VectivBio Announces Closing of Comet Therapeutics Acquisition
- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -
VectivBio Announces Upcoming Investor Events
Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities
VectivBio Announces Results of Extraordinary General Meeting
Paul R. Carter and Murray W. Stewart Elected to the Board of Directors Paul R. Carter and Murray W. Stewart Elected to the Board of Directors
VectivBio to Acquire Comet Therapeutics and Host R&D Day
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021-
VectivBio Publishes Invitation to the Extraordinary General Meeting
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...
VectivBio Nominates Paul R. Carter and Murray W.
- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on Sep...
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Phase 2 trial expected to begin in the first quarter of 2022 Phase 2 trial expected to begin in the first quarter of 2022
VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients wit...
Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population...
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of a...
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of t...
VectivBio Announces Closing of $146.6 Million Initial Public Offering
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...
Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today
Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...
VectivBio Announces Pricing of Initial Public Offering
BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...